Riik: Ameerika Ühendriigid
keel: inglise
Allikas: NLM (National Library of Medicine)
LIDOCAINE HYDROCHLORIDE (UNII: V13007Z41A) (LIDOCAINE - UNII:98PI200987)
Wockhardt USA LLC.
TOPICAL
PRESCRIPTION DRUG
Lidocaine Hydrochloride Topical Solution is indicated for the production of topical anesthesia of accessible mucous membranes of the oral and nasal cavities and proximal portions of the digestive tract. Lidocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type, or to other components of Lidocaine Hydrochloride Topical Solution.
Lidocaine Hydrochloride Topical Solution, USP 4% is supplied in 50 mL bottle (NDC 64679-465-50) and packaged in a carton (NDC 64679-465-51). An aqueous solution for topical application. NOT FOR INJECTION. Store at 20 ° to 25 °C (68 ° to 77 °F) [see USP Controlled Room Temperature]. AVOID FREEZING Rx Only Product No.: 8465 Manufactured By: GROUPE PARIMA Inc. 4450 Cousens Montreal, Quebec, Canada H4S 1X6 Manufactured For: Wockhardt USA, LLC 20 Waterview Blvd., Parsippany, NJ 07054, USA 28465GP REV. 08-22
Abbreviated New Drug Application
LIDOCAINE HYDROCHLORIDE - LIDOCAINE HYDROCHLORIDE SOLUTION WOCKHARDT USA LLC. ---------- LIDOCAINE HYDROCHLORIDE TOPICAL SOLUTION, USP 4% RX ONLY DESCRIPTION Lidocaine Hydrochloride Topical Solution, USP 4% contains a local anesthetic agent and is administered topically. See INDICATIONS for specific uses. Lidocaine Hydrochloride Topical Solution USP 4% contains lidocaine hydrochloride monohydrate, which is chemically designated as 2-(Diethylamino)-2',6'-acetoxylidide monohydrochloride monohydrate and has the following structural formula: C H N O ∙ HCL ∙ H 0 M.W. 288.81 EACH ML CONTAINS: Lidocaine Hydrochloride Monohydrate, 40 USP mg INACTIVE INGREDIENTS: methylparaben, propylene glycol and purified water. IT MAY ALSO CONTAIN sodium hydroxide for pH adjustment. The pH range is between 5.0 and 7.0. An aqueous solution for topical use only. NOT FOR INJECTION. CLINICAL PHARMACOLOGY MECHANISM OF ACTION 14 22 2 2 Lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action. HEMODYNAMICS Excessive blood levels may cause changes in cardiac output, total peripheral resistance, and mean arterial pressure. These changes may be attributable to a direct depressant effect of the local anesthetic agent on various components of the cardiovascular system. The net effect is normally a modest hypotension when the recommended dosages are not exceeded. PHARMACOKINETICS AND METABOLISM Information derived from other formulations, concentrations and usages reveals that lidocaine is completely absorbed following parenteral administration, its rate of absorption depending, for example, upon such factors such as the site of administration and the presence or absence of a vasoconstrictor agent. Lidocaine may be absorbed following topical administration to mucous membranes, its rate of absorption and percent of dose absorbed depending upon concentration and total dose administered, the specific site of application and duration o Lugege kogu dokumenti